The medicine Kisunla (with the substance donanemab) is an antibody that can to some extent slow down the development for patients in the disease's early stage. According to studies, the disease is slowed down by about seven months.
The medicine got the thumbs up from the European Medicines Agency EMA in July this year and now the commission has formally approved it.
Kisunla is the second medicine of its kind on the market in the EU, since the substance lecanemab from Bioarctic was approved under the name Leqembi.
Before Kisunla possibly becomes available to Swedish patients, the expert council NT council must conduct an investigation and come up with a recommendation. What the price will be is also unclear, but according to Dagens Medicin, a year's treatment in the USA costs 32,000 dollars, equivalent to just over 307,000 kronor.
Kisunla is approved for the treatment of patients with mild cognitive impairment or mild dementia due to Alzheimer's disease and who do not carry a double set of the risk gene ApoE4.
